22,260 Amgen Inc. $AMGN Shares Bought by Bath Savings Trust Co

Bath Savings Trust Co raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 2,509.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,147 shares of the medical research company’s stock after purchasing an additional 22,260 shares during the period. Amgen accounts for about 1.0% of Bath Savings Trust Co’s holdings, making the stock its 27th biggest position. Bath Savings Trust Co’s holdings in Amgen were worth $9,757,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp boosted its holdings in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. Bank of America Corp DE purchased a new stake in shares of Amgen in the second quarter worth $1,831,903,000. Wellington Management Group LLP raised its position in shares of Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after buying an additional 2,514,254 shares in the last quarter. BlackRock Inc. boosted its stake in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after buying an additional 2,261,544 shares during the period. Finally, Corient Private Wealth LP purchased a new position in Amgen during the second quarter worth about $187,401,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 2.6%

NASDAQ:AMGN traded up $10.48 during trading hours on Wednesday, reaching $413.08. The company’s stock had a trading volume of 2,236,544 shares, compared to its average volume of 2,758,837. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm has a market capitalization of $223.32 billion, a price-to-earnings ratio of 25.67, a PEG ratio of 2.91 and a beta of 0.41. The firm has a 50-day simple moving average of $411.44 and a 200-day simple moving average of $371.01. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts expect that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s payout ratio is presently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported results from a clinical trial involving a treatment for Sjögren’s disease. The update appears to have supported the stock by providing investors with additional visibility into the company’s immunology pipeline. Amgen announces Sjogren’s trial results
• Positive Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing. The investment could give Amgen access to AI-driven genetic testing and molecular-data capabilities that may improve precision-medicine decisions and the design of genomically targeted clinical trials. Amgen backs Arboretum LifeSciences Series A
• Positive Sentiment: Amgen’s AMG 513 obesity study reached Phase 1 completion. While early-stage completion does not establish efficacy, the program adds another potential growth opportunity as the company competes in the weight-loss drug market. Amgen AMG 513 obesity trial update
• Neutral Sentiment: Cantor Fitzgerald maintained a Neutral rating, while another report cited a Neutral rating with a $400 price target. These views suggest analysts see limited near-term upside after the recent advance. Cantor Fitzgerald maintains Neutral rating
• Neutral Sentiment: A former Amgen commercial leader joined Entera Bio, a move relevant to Entera rather than Amgen and unlikely to materially affect AMGN’s fundamentals. Former Amgen leader joins Entera
• Negative Sentiment: Morgan Stanley lowered its price target to $359 while maintaining an Equal Weight rating, and Truist raised its target to $380 but kept a Hold rating. Both targets remain below the current share price, signaling valuation concerns and potential downside. Morgan Stanley lowers Amgen price target Truist raises Amgen price target

Wall Street Analysts Forecast Growth

Several analysts have weighed in on AMGN shares. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $450.00 price target on the stock. in a report on Tuesday, September 8th. Piper Sandler upped their price objective on shares of Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Morgan Stanley cut their price target on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Guggenheim increased their price target on shares of Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $385.79.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.